280 related articles for article (PubMed ID: 32230980)
1. Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib.
Liu G; Jin Z; Lu X
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230980
[TBL] [Abstract][Full Text] [Related]
2. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
Feng S; Cheng X; Zhang L; Lu X; Chaudhary S; Teng R; Frederickson C; Champion MM; Zhao R; Cheng L; Gong Y; Deng H; Lu X
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):10094-10099. PubMed ID: 30232256
[TBL] [Abstract][Full Text] [Related]
4. Enhancing immune checkpoint blockade therapy of genitourinary malignancies by co-targeting PMN-MDSCs.
Lu X; Lu X
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188702. PubMed ID: 35227829
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
Park H; Kim Y; Sul JW; Jeong IG; Yi HJ; Ahn JB; Kang JS; Yun J; Hwang JJ; Kim CS
Prostate; 2015 Nov; 75(15):1747-59. PubMed ID: 26250606
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma.
Yu GT; Mao L; Wu L; Deng WW; Bu LL; Liu JF; Chen L; Yang LL; Wu H; Zhang WF; Sun ZJ
Cell Mol Life Sci; 2018 Nov; 75(22):4223-4234. PubMed ID: 29955905
[TBL] [Abstract][Full Text] [Related]
7. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the therapeutic potential of GANT61/Dactolisib combination as a novel prostate cancer modality.
Youssef M; Moussa N; W Helmy M; Haroun M
Med Oncol; 2022 Jul; 39(10):143. PubMed ID: 35834137
[TBL] [Abstract][Full Text] [Related]
9. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
10. Positive Pelvic Lymph Nodes in Prostate Cancer Harbor Immune Suppressor Cells To Impair Tumor-reactive T Cells.
Sharma V; Dong H; Kwon E; Karnes RJ
Eur Urol Focus; 2018 Jan; 4(1):75-79. PubMed ID: 28753790
[TBL] [Abstract][Full Text] [Related]
11. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
Cao L; Dai C; Qin R; Guo Y; Liu J
Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
[No Abstract] [Full Text] [Related]
12. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
[TBL] [Abstract][Full Text] [Related]
13. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
[TBL] [Abstract][Full Text] [Related]
14. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
[TBL] [Abstract][Full Text] [Related]
15. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
[TBL] [Abstract][Full Text] [Related]
16. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
17. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
[TBL] [Abstract][Full Text] [Related]
18. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
[TBL] [Abstract][Full Text] [Related]
20. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
Front Immunol; 2021; 12():754196. PubMed ID: 35003065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]